Mr. Amir Reichman M.B.A., M.Sc.
CEO & Director
Biography unavailable
Scinai Immunotherapeutics Ltd
F:2F50
Scinai Immunotherapeutics Ltd
F:2F50
Price:
4.04
EUR
5.21%
Market Closed
Market Cap:
€234.8k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Scinai Immunotherapeutics Ltd
F:2F50
|
IL |
|
P
|
PT Adaro Andalan Indonesia Tbk
IDX:AADI
|
ID |
|
H
|
Hess Corp
SWB:AHC
|
US |
|
Eastern International Ltd
NASDAQ:ELOG
|
CN |
|
S
|
Solvay SA
DUS:SOL
|
BE |
|
N
|
Nintendo Co Ltd
XMUN:NTO
|
JP |
|
O
|
Orlen SA
PSE:PKN
|
PL |
|
Nintendo Co Ltd
OTC:NTDOF
|
JP |
|
A
|
Air Canada
F:ADH2
|
CA |
|
M
|
Mattel Inc
XHAM:MTT
|
US |
|
S
|
Shanghai Chengtou Holding Co Ltd
SSE:600649
|
CN |
|
Braime Group PLC
LSE:BMTO
|
UK |
|
P
|
PetroChina Co Ltd
XMUN:PC6
|
CN |
|
F
|
Fruitas Holdings Inc
XPHS:FRUIT
|
PH |
|
Air Canada
TSX:AC
|
CA |
|
Credit Agricole SA
F:XCA
|
FR |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- Israel IL
- Employees
- 45
- IPO date
- Jun 7, 2007
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Continue 2F50 Research
Other Scinai Immunotherapeutics Ltd listings:
